Try

Schrodinger, Inc.

SDGRUnited States

35 filed reports · 328 financial concepts · 1 earnings calls · 0 media appearances

Filed reports

35 reports · Mar 2020 to Jun 2026

Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 20 guidance figures.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR203,369Mar 2020 to Jun 2026
Current · 8-KSEC EDGAR920Dec 2020 to Jun 2026
Annual · 10-KSEC EDGAR62,713Dec 2020 to Dec 2025

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q210-QJun 30, 2026Aug 5, 2026348Open
FY2026 Q28-KJun 30, 2026Aug 5, 20262Open
FY2026 Q110-QMar 31, 2026May 5, 2026230Open
FY202510-KDec 31, 2025Feb 25, 2026883Open
FY2025 Q310-QSep 30, 2025Nov 5, 2025240Open
FY2025 Q210-QJun 30, 2025Aug 6, 2025141Open
FY2025 Q110-QMar 31, 2025May 7, 2025141Open
FY202410-KDec 31, 2024Feb 26, 2025378Open
FY2024 Q310-QSep 30, 2024Nov 12, 2024166Open
FY2024 Q210-QJun 30, 2024Jul 31, 2024151Open
FY2024 Q110-QMar 31, 2024May 1, 2024143Open
FY202310-KDec 31, 2023Feb 28, 2024432Open

Financial data

328 concepts · 6,102 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial313 concepts · 5,249 facts · Mar 2019 to Jun 2026

  • Adjustments to additional paid in capital sharebased compensation requisite service period recognition value37 · Mar 2019 to Jun 2026
  • Allocated share based compensation expense37 · Mar 2019 to Jun 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents37 · Mar 2019 to Jun 2026
  • Comprehensive income net of tax37 · Mar 2019 to Jun 2026
  • Cost of revenue (US GAAP)37 · Mar 2019 to Jun 2026
  • General and administrative expense (US GAAP)37 · Mar 2019 to Jun 2026
  • Gross profit (US GAAP)37 · Mar 2019 to Jun 2026
  • Income taxes paid net37 · Mar 2019 to Jun 2026
  • Income tax expense benefit37 · Mar 2019 to Jun 2026
  • Increase decrease in accounts payable37 · Mar 2019 to Jun 2026
  • Increase decrease in accounts receivable37 · Mar 2019 to Jun 2026
  • Increase decrease in employee related liabilities37 · Mar 2019 to Jun 2026
  • Increase decrease in equity securities fv ni37 · Mar 2019 to Jun 2026
  • Increase decrease in other accrued liabilities37 · Mar 2019 to Jun 2026
  • Increase decrease in prepaid deferred expense and other assets37 · Mar 2019 to Jun 2026
  • Net cash provided by used in financing activities37 · Mar 2019 to Jun 2026
  • Net cash provided by used in investing activities37 · Mar 2019 to Jun 2026
  • Net cash provided by used in operating activities37 · Mar 2019 to Jun 2026
  • Net income loss37 · Mar 2019 to Jun 2026
  • Nonoperating income expense37 · Mar 2019 to Jun 2026
  • Operating expenses (US GAAP)37 · Mar 2019 to Jun 2026
  • Operating income loss37 · Mar 2019 to Jun 2026
  • Other comprehensive income unrealized holding gain loss on securities arising during period net of tax37 · Mar 2019 to Jun 2026
  • Payments to acquire marketable securities37 · Mar 2019 to Jun 2026

Product6 concepts · 493 facts · Mar 2019 to Jun 2026

  • Revenue295 · Mar 2019 to Jun 2026
  • Cost of revenue (US GAAP)78 · Mar 2019 to Jun 2026
  • Drug Discovery Services44 · Mar 2019 to Jun 2026
  • Drug discovery contribution36 · Dec 2019 to Sep 2024
  • Revenue not from contract with customer28 · Dec 2020 to Dec 2025
  • Contract with customer liability revenue recognized12 · Mar 2025 to Jun 2026

Segment3 concepts · 176 facts · Mar 2019 to Jun 2026

  • Gross profit (US GAAP)74 · Mar 2019 to Jun 2026
  • Revenue74 · Mar 2019 to Jun 2026
  • Cost of revenue (US GAAP)28 · Dec 2022 to Jun 2026

Geography4 concepts · 164 facts · Mar 2019 to Jun 2026

  • Revenue160 · Mar 2019 to Jun 2026
  • Revenue from contracts with customers (excluding tax)2 · Dec 2021 to Dec 2022
  • Increase in right-of-use assets1 · Mar 2022
  • Revenue (excluding assessed tax)1 · Dec 2022

Guidance2 concepts · 20 facts · Mar 2021 to Aug 2026

  • Revenue Guidance18 · Mar 2021 to Aug 2026
  • Gross Margin Guidance2 · May 2022

Segments

833 facts

Figures broken down by business line, region, product or another axis the company reports on.

Product or service13 members · 493 facts

  • Drug Discovery95 · Mar 2019 to Jun 2026
  • Software Products And Services78 · Mar 2019 to Jun 2026
  • Drug Discovery Services39 · Dec 2019 to Dec 2025
  • Hosted Software37 · Mar 2019 to Jun 2026
  • Maintenance37 · Mar 2019 to Jun 2026
  • On Premise Software37 · Mar 2019 to Jun 2026
  • Professional Services37 · Mar 2019 to Jun 2026
  • Drug Discovery Contribution34 · Dec 2020 to Jun 2026
  • Contribution26 · Jun 2020 to Jun 2026
  • Drug Discovery Services Revenue From Contracts With Customers23 · Dec 2019 to Sep 2024
  • Software Contribution22 · Dec 2020 to Jun 2026
  • Revenue From Contract With Customer Before Contribution21 · Jun 2019 to Sep 2025
  • Revenue From Contract With Customer Before Software Contribution7 · Dec 2019 to Dec 2025

Statement business segments2 members · 176 facts

  • Drug Discovery88 · Mar 2019 to Jun 2026
  • Software88 · Mar 2019 to Jun 2026

Statement geographical8 members · 164 facts

  • Non Us39 · Mar 2019 to Jun 2026
  • US37 · Mar 2019 to Jun 2026
  • APAC22 · Dec 2021 to Jun 2026
  • EMEA22 · Dec 2021 to Jun 2026
  • Europe21 · Mar 2019 to Mar 2023
  • JP21 · Mar 2019 to Mar 2023
  • Us1 · Dec 2022
  • NY1 · Mar 2022

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

1 calls · Aug 2026

Transcripts with management claims and analyst questions, one per fiscal period.

  • FY2026 Q2Aug 5, 2026

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.

Schrodinger, Inc. (SDGR) data · FactIQ